Patents Assigned to Merck
  • Formulations of dengue virus vaccine compositions
    Patent number: 12208135
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Grant
    Filed: December 6, 2023
    Date of Patent: January 28, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • LIQUID-CRYSTALLINE MEDIA
    Publication number: 20250026983
    Abstract: The invention relates to liquid-crystalline media which can be used, in particular, for electro-optical displays having active-matrix addressing based on the ECB effect and for IPS (in-plane switching) displays or FFS (fringe field switching) displays.
    Type: Application
    Filed: September 16, 2024
    Publication date: January 23, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Melanie Klasen-Memmer, Marcus Reuter, Rocco Fortte, Detlef Pauluth, Matthias Bremer, Helmut Haensel, Harald Hirschmann
  • FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20250026762
    Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
    Type: Application
    Filed: November 28, 2022
    Publication date: January 23, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mark E. Fraley, Tao Liang, H. Marie Loughran, Anthony J. Roecker, Kathy M. Schirripa, Ling Tong, Ashwin U. Rao
  • TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS
    Publication number: 20250026759
    Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: July 5, 2024
    Publication date: January 23, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael J. Breslin, Antonella Converso, Abdellatif El Marrouni, Ashley Forster, David N. Hunter, Anthony W. Shaw, William D. Shipe, Yunlong Zhang
  • Aromatic isothiocyanates
    Patent number: 12203023
    Abstract: The present invention relates to a compound of formula GF in which the occurring groups and parameters have the meanings defined in claim 1, to a liquid crystal medium comprising a compound of formula GF and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: January 21, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Constanze Brocke, Dagmar Klass, Carsten Fritzsch
  • CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS
    Publication number: 20250019376
    Abstract: The present invention relates to monobactam compounds of Formula I: The present invention also relates to pharmaceutical compositions comprising a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof. The invention further relates to the compounds of formula (I) for use in methods for treating a bacterial infection, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. The present invention discloses the synthesis and characterisation of exemplary compounds as well as biological assays thereof. An exemplary compound is e.g.
    Type: Application
    Filed: November 16, 2022
    Publication date: January 16, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Helen Y. Chen, Shuzhi Dong, Zhiyong Hu, Jing Su, Tao Yu, Yong Zhang
  • 5-azaindazole derivatives as adenosine receptor antagonists
    Patent number: 12194051
    Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 14, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Anne-Laure Blayo, Baptiste Manteau, Camille Amalric, Stanislas Mayer, Stephan Schann, Mickaël Fer
  • 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors
    Patent number: 12195445
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: January 14, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • Organometallic compounds and thin film using same
    Patent number: 12195488
    Abstract: According to the organometallic compound of the present invention and the thin film manufactured using the same, requirements of high volatility and excellent chemical/thermal stability are satisfied, and significantly improved thin-film deposition rates are exhibited even at low temperatures. In addition, property degradation due to by-products can be improved, excellent step coverage can be realized, and a thin film which, due to having a high dielectric constant, electrically satisfies the equivalent oxide thickness (EOT) requirement while having a thickness at which tunneling does not physically occur can be implemented.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: January 14, 2025
    Assignee: Merck Patent GMBH
    Inventors: Seung Won Ha, Young Hun Byun, Jeum Jong Kim, Ho Hoon Kim, Seong Hak Cheon
  • Antiproliferation compounds and uses thereof
    Patent number: 12195453
    Abstract: The present invention provides compounds of Formula I?, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: January 14, 2025
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Henry Yu, Michael Clark, Guy Bemis, Michael Boyd, Kishan Chandupatla, Philip Collier, Hongbo Deng, Huijun Dong, Warren Dorsch, Russell R. Hoover, Mac Arthur Johnson, Jr., Shashank Kulkarni, Marina Penney, Steven Ronkin, Darin Takemoto, Qing Tang, Nathan D. Waal, Tiansheng Wang, David J. Lauffer, Pan Li
  • SCALABLE CHROMATOGRAPHY PROCESS FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
    Publication number: 20250011732
    Abstract: The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.
    Type: Application
    Filed: July 11, 2024
    Publication date: January 9, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Adam Kristopeit, Janelle Konietzko, Wanli MA, Katherine Phillips, Andrew Swartz, Sheng-Ching Wang, Marc D. Wenger, Matthew Woodling, Tiago Matos
  • FORMULATIONS OF ANTIVIRAL COMPOUNDS
    Publication number: 20250009751
    Abstract: The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C virus NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.
    Type: Application
    Filed: September 23, 2024
    Publication date: January 9, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Sutthilug Sotthivirat, Joyce Stellabott, Walter R. Wasylaschuk
  • METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS
    Publication number: 20250011453
    Abstract: Provided herein are methods of treating cancer (e.g., ovarian, mesothelioma, triple-negative breast cancer), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.
    Type: Application
    Filed: July 18, 2022
    Publication date: January 9, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventor: Rachel A. Altura
  • Nitrogen-containing heterocycles for use in OLEDs
    Patent number: 12193325
    Abstract: The present invention describes nitrogen-containing heterocycles substituted by carbazole groups, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: January 7, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Amir Parham, Jonas Kroeber, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann, Philipp Stoessel, Christian Eickhoff
  • Non-woven fiber membranes
    Patent number: 12186713
    Abstract: Provided herein are electrospun or electroblown non-woven fiber membranes, methods of making such membranes and lateral flow diagnostic devices comprising such membranes.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: January 7, 2025
    Assignees: Merck Millipore Ltd., The Provost Fellows Foundation Scholars and the Other Members of Board of the College of the Holy Cross
    Inventors: William Cataldo, Inga Elkina, Kamran Beyzavi, Thomas Fitzgerald, Dennis Aquino, Daniel Callahan, Michael Mansfield, Mikhail Kozlov, Gabriel Tkacik, Murugan Rajendiran, Ramesh Babu Padamati
  • Polymerisable liquid crystal material and polymerised liquid crystal film
    Patent number: 12187946
    Abstract: A polymerisable LC material comprising one or more di- or multireactive mesogenic compounds and one or more compounds of formula UVI, and one or more compounds of formula UVII, Further, a method for its preparation, a polymer film with improved thermal durability and UV stability obtainable from a corresponding polymerisable LC material, a method of preparation of such polymer film, and the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 7, 2025
    Assignee: Merck Patent GmbH
    Inventors: Jin-Soon Park, Hoo-Yong Lee, Hyun-Jin Yoon, Heui-Seok Jin
  • Liquid-crystal medium
    Patent number: 12187944
    Abstract: A liquid-crystal (LC) medium which is based on a mixture of polar compounds and is substantially dielectrically neutral, its use for optical, electro-optical and electronic purposes, in particular as optical retarder or optical compensator in LC displays, an optical retarder or optical compensator containing the LC medium, an optical, electrooptical or electronic device containing the optical retarder or optical compensator, and a process of manufacturing the optical retarder or optical compensator.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: January 7, 2025
    Assignee: Merck Patent GmbH
    Inventors: Sven Christian Laut, Tzu-Huan Tseng, Kuang-Ting Chou, Chi-Shun Huang
  • Aromatic compounds and use thereof for formation of molecular layers and fabrication of switching elements for memristive devices
    Patent number: 12193328
    Abstract: The present invention relates to a compounds of formula I R1-(A1-Z1)r—B1—ZL-A2-(Z3-A3)s-G??(I) in which the occurring groups and parameters have the meanings given in claim 1, to the use thereof for the formation of molecular layers, in particular self assembled monolayers, to a process for the fabrication of a switching element for memristive devices comprising said molecular layers and to a memristic device comprising said switching element.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: January 7, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Sebastian Resch, Henning Seim
  • AMPOULE FOR ORAL VACCINE ADMINISTRATION AND METHODS OF USE
    Publication number: 20250000744
    Abstract: An ampoule includes a body having a cavity for storing a medicament, a neck coupled to the body and defining a nozzle in communication with the cavity of the body, a removable cap coupled to the nozzle, and an anti-choking miter coupled to the removable cap, the anti-chocking miter being wider than the removable cap.
    Type: Application
    Filed: November 11, 2022
    Publication date: January 2, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ramprasad B. Halthore, Atul Karande, Derrick M. Smith
  • ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20250002448
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of a7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease. Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: September 19, 2022
    Publication date: January 2, 2025
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Ian M. Bell, Brendan M. Crowley, James Fells, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Belinda C. Huff, Christophe Joseph, Christophe Morice, Dharam Paul, Aurelie Witzel